José Valdez Madruga

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

José Valdez Madruga, Pedro Cahn, Beatriz Grinsztejn et al. · The Lancet · 2007 · 516 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11

Mpox in people with advanced HIV infection: a global case series

Andrea Alemany, Michael Marks, Jezer I Lezama Mora et al. · The Lancet · 2023 · 485 citations · Full text

Public Health, Immunology, Infectious Diseases +9

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

José Valdez Madruga, Daniel Berger, Marilyn McMurchie et al. · The Lancet · 2007 · 332 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

Anthony Mills, José Ramón Arribas, Jaime Andrade‐Villanueva et al. · The Lancet Infectious Diseases · 2015 · 304 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

Colleen F. Kelley, Maribel Acevedo-Quiñones, Allison L. Agwu et al. · New England Journal of Medicine · 2024 · 229 citations

Public Health, Pharmacology, Pharmacotherapy +17